Medical injury product and diagnostic start-up, Medpoint has formally launched its €400k seed funding round to investors in order to ramp up its sales and marketing plans and double its turnover over the next two years. It has already raised 60% of its seed funding round and is targeting EIIS investors in the run up to tax deadlines and year end.
CEO, Neil Brown who founded the company said that there is a significant and growing demand in the important healthcare market of injury management, ergonomics, exercise, rehabilitation and near patient testing.
Of particular interest to Medpoint is the Ergonomic and Clinical Equipment market where the company sees significant opportunities to specialise in Neck Pain products. Many studies over the years have pointed to an annual prevalence rate in the population of between 30% and 50% with women reporting higher statistically.
As a result of this, Medpoint recently announced partnerships with two European Ergonomic Manufacturers, elsa of Switzerland and Reha Fund of Poland.
Medpoint sources and distributes a range of healthcare and diagnostic products for its expanding customer base includes Doctors, Physiotherapists, Nursing Homes, Chiropractors, Pharmacies and professional sporting organisations.
The company is also growing its staff numbers and plans to have 10 employed by the end of 2023.
EIIS Investors who are looking to save tax in the run up to filing deadlines can reclaim up to 40% of their investment in the form of a Tax refund. We have already seen significant enquiries regarding EIIS says Brown and this will only increase further as we approach the 31st December.
The founder Neil Brown has over 25 years’ experience in growing and scaling businesses in a variety of sectors including seven years in the medical and biotechnology industry. An experienced entrepreneur and accountant by profession, he started and trained in BDO and Mazars before setting up a Corporate Care business which he later sold to Nasdaq quoted Bright Horizons Family
Pictured: Neil Brown Founder. Lisa Mitchell, Director